Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ultragenyx Pharmaceu
(NQ:
RARE
)
44.24
+0.39 (+0.89%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
450,422
Open
44.16
Bid (Size)
44.23 (1)
Ask (Size)
44.25 (30)
Prev. Close
43.85
Today's Range
43.71 - 44.58
52wk Range
31.52 - 54.56
Shares Outstanding
70,814,462
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
April 25, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical
April 22, 2024
Via
Benzinga
Performance
YTD
-8.16%
-8.16%
1 Month
-2.68%
-2.68%
3 Month
-2.23%
-2.23%
6 Month
+28.19%
+28.19%
1 Year
+4.51%
+4.51%
More News
Read More
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 19, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
April 15, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 9 Analysts
April 05, 2024
Via
Benzinga
Analyst Scoreboard: 8 Ratings For Ultragenyx Pharmaceutical
March 18, 2024
Via
Benzinga
Recap: Ultragenyx Pharmaceutical Q4 Earnings
February 15, 2024
Via
Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 15, 2024
Via
Benzinga
Crude Oil Down 1%; Charles Schwab Sales Top Estimates
April 15, 2024
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
The Latest Analyst Ratings For Ultragenyx Pharmaceutical
February 15, 2024
Via
Benzinga
Earnings Scheduled For February 15, 2024
February 15, 2024
Via
Benzinga
Preview: Ultragenyx Pharmaceutical's Earnings
February 14, 2024
Via
Benzinga
Rare Disease-Focused-Ultragenyx Pharmaceutical Stock Falls On Serious Adverse Events In Eaarly Genetic Disorder Study
April 15, 2024
Via
Benzinga
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
April 15, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
April 15, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
April 12, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
April 12, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 22, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Participate at Investor Conferences in March
February 27, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 23, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
February 15, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
February 08, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)
February 06, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
February 05, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
January 25, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.